News
In just eight years, the NIH National Institute of Allergy and Infectious Diseases moved from identifying an ultra-rare genetic disorder, CD55 deficiency, hyperactivation of the complement, angiopathic thrombosis, and protein-losing enteropathy (CHAPLE) to FDA approval of its first treatment option
Register to attend a free NCI webinar. Attendees will learn about a new a djuvanted subunit mucosal Covid-19 vaccine. Study results show that this new vaccine prevents SARS-CoV-2 transmission and infection. Most SARS-CoV-2 vaccines focus on delivering immunization through an intramuscular injection
NIH is dedicated to researching rare diseases and collaborating with partners to bring products for rare diseases to market, not only during Rare Disease Week but throughout the year. As a result of such work, on November 22, 2022, the U.S. Food and Drug Administration approved Hemgenix®, the world
Are you interested in making an impact on the improvement of global health? Are you interested in working in a dynamic organization that values its employees and offers work-life flexibility? The National Institute of Allergy and Infectious Diseases (NIAID), one of the largest Institutes at the